GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Infant Bacterial Therapeutics AB (STU:9IB) » Definitions » PB Ratio

Infant Bacterial Therapeutics AB (STU:9IB) PB Ratio : 3.39 (As of Dec. 14, 2024)


View and export this data going back to 2017. Start your Free Trial

What is Infant Bacterial Therapeutics AB PB Ratio?

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2024-12-14), Infant Bacterial Therapeutics AB's share price is €4.52. Infant Bacterial Therapeutics AB's Book Value per Share for the quarter that ended in Sep. 2024 was €1.33. Hence, Infant Bacterial Therapeutics AB's PB Ratio of today is 3.39.

The historical rank and industry rank for Infant Bacterial Therapeutics AB's PB Ratio or its related term are showing as below:

STU:9IB' s PB Ratio Range Over the Past 10 Years
Min: 0.63   Med: 1.99   Max: 10.02
Current: 4.12

During the past 10 years, Infant Bacterial Therapeutics AB's highest PB Ratio was 10.02. The lowest was 0.63. And the median was 1.99.

STU:9IB's PB Ratio is ranked worse than
63.31% of 1281 companies
in the Biotechnology industry
Industry Median: 2.48 vs STU:9IB: 4.12

During the past 12 months, Infant Bacterial Therapeutics AB's average Book Value Per Share Growth Rate was -41.00% per year. During the past 3 years, the average Book Value Per Share Growth Rate was -16.70% per year. During the past 5 years, the average Book Value Per Share Growth Rate was -14.10% per year.

During the past 10 years, the highest 3-Year average Book Value Per Share Growth Rate of Infant Bacterial Therapeutics AB was 90.70% per year. The lowest was -16.70% per year. And the median was 19.60% per year.

Back to Basics: PB Ratio


Infant Bacterial Therapeutics AB PB Ratio Historical Data

The historical data trend for Infant Bacterial Therapeutics AB's PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Infant Bacterial Therapeutics AB PB Ratio Chart

Infant Bacterial Therapeutics AB Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3.05 2.76 1.82 1.64 3.94

Infant Bacterial Therapeutics AB Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.14 3.94 3.67 5.35 2.11

Competitive Comparison of Infant Bacterial Therapeutics AB's PB Ratio

For the Biotechnology subindustry, Infant Bacterial Therapeutics AB's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Infant Bacterial Therapeutics AB's PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Infant Bacterial Therapeutics AB's PB Ratio distribution charts can be found below:

* The bar in red indicates where Infant Bacterial Therapeutics AB's PB Ratio falls into.



Infant Bacterial Therapeutics AB PB Ratio Calculation

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.

Infant Bacterial Therapeutics AB's PB Ratio for today is calculated as follows:

PB Ratio=Share Price/Book Value per Share (Q: Sep. 2024)
=4.52/1.334
=3.39

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.


Infant Bacterial Therapeutics AB  (STU:9IB) PB Ratio Explanation

Unlike valuation ratios relative to the earning power such as PE Ratio, PE Ratio without NRI, PS Ratio, Price-to-Operating-Cash-Flow , or Price-to-Free-Cash-Flow, the PB Ratio measures the valuation of the stock relative to the underlying asset of the company.

The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.


Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.


Infant Bacterial Therapeutics AB PB Ratio Related Terms

Thank you for viewing the detailed overview of Infant Bacterial Therapeutics AB's PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Infant Bacterial Therapeutics AB Business Description

Traded in Other Exchanges
Address
Bryggargatan 10, Stockholm, SWE, 111 21
Infant Bacterial Therapeutics AB is a pharmaceutical company. Its purpose is to develop and commercialize drugs for diseases affecting premature babies. Its focus is on the drug candidate IBP-9414, whose development program is designed to show a reduced incidence of necrotizing enterocolitis (NEC) and improved gastrointestinal function (SFT) when treated with IBP-9414's active substance Lactobacillus reuteri bacterial strain naturally found in human breast milk. Its portfolio also includes additional drug candidates, IBP-1016, IBP-1118 and IBP-1122. IBP1016, for the treatment of gastroschisis, is a life-threatening and rare disorder in which children are born with externalized gastrointestinal organs.

Infant Bacterial Therapeutics AB Headlines

No Headlines